Drug Safety Settlement

A Ranbaxy office building is pictured in the northern Indian city of Mohali May 14, 2013. Indian generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice. The settlement is its largest-ever with a generic drugmaker over drug safety, according to the U.S. government. It includes $150 million in payments for a criminal fine and forfeiture and $350 million in payments for civil claims. REUTERS/Ajay Verma (INDIA - Tags: HEALTH BUSINESS)

Daiichi Sankyo says it was misled over Ranbaxy U.S. probes

Japanese drugmaker Daiichi Sankyo Co, which bought control of Ranbaxy Laboratories in 2008, said it believes unnamed former shareholders of the company hid information regarding U.S. regulatory probes into Ranbaxy.  Full Article 

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Bernanke Testimony

Bernanke Testimony

Bernanke says more progress needed before stimulus pullback.  Full Article 

Galaxy S4 Sales

Galaxy S4 Sales

Samsung says Galaxy S4 sales hit 10 million.  Full Article 

Copper Shortage

Copper Shortage

Copper smelter closures put cable makers in tight spot.  Full Article 

Tax Avoidance

Tax Avoidance

EU leaders talk tough on tackling Amazon, Google over taxes.  Full Article | Related Story 

Anti-Hacking Move

Anti-Hacking Move

Twitter beefs up security after hacking spree on media.  Full Article 

Bank Unit Acquisition

Bank Unit Acquisition

Srei Infrastructure to buy Austrian bank unit - paper  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Market Eye Weekahead - Infosys kicks off blue-chip results

Related Topics

Stocks

   
Track BSE Sectoral Indices

Track Markets: BSE Sectoral Indices

Track and analyse performance of all BSE sectoral indices and other global indices on a single page.   Full Coverage 

An employees walks past a signage board in the Infosys campus at the Electronics City IT district in Bangalore, February 28, 2012. REUTERS/Vivek Prakash/Files

An employees walks past a signage board in the Infosys campus at the Electronics City IT district in Bangalore, February 28, 2012.

Credit: Reuters/Vivek Prakash/Files

Fri Jan 4, 2013 4:58pm IST

Market Eye Weekahead - Indian markets are expected to remain in a narrow range ahead of the October-December quarterly results from IT bellwether Infosys Ltd (INFY.NS) on Friday, which will kick off the earnings reporting season.

Industrial output is also due on Friday, a key indicator ahead of the RBI's policy review on January 29.

The gains come as India's indexes have gained in each of the four trading sessions so far in 2013, posting their best weekly gains since the week ended on November 30.

Telecom stocks could also be in focus as an Indian ministerial panel is due to meet on Monday to discuss the government's plans for the next airwave auction.

KEY FACTORS TO WATCH

Mon: Telecoms panel meeting on airwave auction; coal-power inter-ministerial meeting on long-term supply pacts in India's power sector

Tue: Karnataka iron ore case arguments in Indian top court

Wed: IndusInd Bank Ltd Oct-Dec earnings

Fri: Infosys' Oct-Dec earnings; Nov industrial output

(Reporting by Manoj Dharra)
Business
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.